Matches in Wikidata for { <http://www.wikidata.org/entity/Q65381399> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q65381399 description "assaig clínic" @default.
- Q65381399 description "clinical trial" @default.
- Q65381399 description "clinical trial" @default.
- Q65381399 description "clinical trial" @default.
- Q65381399 description "clinical trial" @default.
- Q65381399 description "ensaio clínico" @default.
- Q65381399 description "ensayo clínico" @default.
- Q65381399 description "ensayu clínicu" @default.
- Q65381399 description "essai clinique" @default.
- Q65381399 description "klinisch onderzoek" @default.
- Q65381399 description "клінічне випробування" @default.
- Q65381399 name "Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia" @default.
- Q65381399 name "Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia" @default.
- Q65381399 type Item @default.
- Q65381399 label "Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia" @default.
- Q65381399 label "Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia" @default.
- Q65381399 prefLabel "Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia" @default.
- Q65381399 prefLabel "Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia" @default.
- Q65381399 P1050 Q65381399-43CD92FA-BD9E-45C4-89AC-8B6DD5942C9E @default.
- Q65381399 P1132 Q65381399-31DA2E9F-9C81-481A-8D2F-F724DCA742A2 @default.
- Q65381399 P1476 Q65381399-1C6BFC78-F2A4-4158-861B-3F7F84F42CBA @default.
- Q65381399 P17 Q65381399-E7B8D7F4-03DB-430E-B4B1-DAB0D9D7F365 @default.
- Q65381399 P2899 Q65381399-15A1025B-C773-4362-8339-BF8E277CC001 @default.
- Q65381399 P3098 Q65381399-304DEF67-9B68-4697-85FC-FA104D2584B3 @default.
- Q65381399 P31 Q65381399-BD9F3557-98E2-4240-AF53-B6C44AF68AA1 @default.
- Q65381399 P4135 Q65381399-91449125-8678-40C9-9A2F-4226AE8E302A @default.
- Q65381399 P4844 Q65381399-00A6BF25-5748-4886-9B2F-DFE6A7F0590D @default.
- Q65381399 P4844 Q65381399-3DE640B4-C3A9-4BF3-A199-7C9818094577 @default.
- Q65381399 P580 Q65381399-70C5E385-A185-4AF2-AD70-4C8D018EBC96 @default.
- Q65381399 P582 Q65381399-442A7D5A-9BD8-4D13-8EF7-C8420FCD97AB @default.
- Q65381399 P6099 Q65381399-C996356E-0F37-4592-AF40-3F660F9643A9 @default.
- Q65381399 P8363 Q65381399-3C341A24-9791-4BC7-8B79-D44B2F5C5C93 @default.
- Q65381399 P1050 Q29496 @default.
- Q65381399 P1132 "+111" @default.
- Q65381399 P1476 "Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML)" @default.
- Q65381399 P17 Q30 @default.
- Q65381399 P2899 "+16" @default.
- Q65381399 P3098 "NCT00528398" @default.
- Q65381399 P31 Q30612 @default.
- Q65381399 P4135 "+60" @default.
- Q65381399 P4844 Q1063862 @default.
- Q65381399 P4844 Q180983 @default.
- Q65381399 P580 "1994-09-01T00:00:00Z" @default.
- Q65381399 P582 "2015-12-01T00:00:00Z" @default.
- Q65381399 P6099 Q42824440 @default.
- Q65381399 P8363 Q78089383 @default.